Status:

UNKNOWN

EDIT Management Feasibility Trial

Lead Sponsor:

NHS Greater Glasgow and Clyde

Collaborating Sponsors:

Rocket Medical plc

Conditions:

Pleural Effusion, Malignant

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

Malignant Pleural Effusion (MPE) is a collection of fluid inside the chest caused by cancer. It is a common medical problem and often causes severe breathlessness. Patients with this condition general...

Eligibility Criteria

Inclusion

  • Clinically confident diagnosis of malignant pleural effusion, defined as any of the following:
  • Pleural effusion with histocytologically proven pleural malignancy OR
  • Pleural effusion in the context of histocytologically proven malignancy elsewhere, without a clear alternative cause for fluid OR
  • Pleural effusion with typical features of malignancy with pleural involvement on cross-sectional imaging (CT/MRI)
  • Degree of breathlessness for which therapeutic pleural intervention would be offered
  • Age \>18 years
  • Expected survival \> 3 months
  • Written Informed Consent

Exclusion

  • Females who are pregnant or lactating
  • Clinical suspicion of non-expansile lung for which talc pleurodesis would not be offered
  • Patient preference for 1st-line indwelling pleural catheter (IPC) insertion
  • Previous ipsilateral failed talc pleurodesis
  • Estimated pleural fluid volume ≤ 1 litre, as defined by thoracic ultrasound
  • Any contraindication to chest drain or IPC insertion, including:
  • Irreversible coagulopathy Inaccessible pleural collection, including lack of suitable IPC tunnel site
  • \- Any contraindication to MRI scanning, including:
  • Claustrophobia Cardiac pacemaker Ferrous metal implants or retained ferrous metal foreign body Previously documented reaction to Gadolinium-containing intravenous contrast agent Significant renal impairment (eGFR\<30 ml/min)

Key Trial Info

Start Date :

August 28 2017

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

November 1 2018

Estimated Enrollment :

30 Patients enrolled

Trial Details

Trial ID

NCT03319186

Start Date

August 28 2017

End Date

November 1 2018

Last Update

October 24 2017

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Queen Elizabeth University Hospital

Glasgow, United Kingdom